אקטמרה 20 מגמל I.V. ישראל - עברית - Ministry of Health

אקטמרה 20 מגמל i.v.

roche pharmaceuticals (israel) ltd - tocilizumab - תרכיז להכנת תמיסה לאינפוזיה - tocilizumab 20 mg/ml - tocilizumab - tocilizumab - actemra (tocilizumab) is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more dmards (disease modifying antirhematic drugs) or tnf antagonists or in whom dmards cannot be used. actemra can be used alone or in combination with methotrexate or other dmards.actemra® has been shown to reduce progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. actemra® is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

אקטמרה 162 מג S.C. ישראל - עברית - Ministry of Health

אקטמרה 162 מג s.c.

roche pharmaceuticals (israel) ltd - tocilizumab - תמיסה להזרקה - tocilizumab 162 mg / 0.9 ml - tocilizumab

קימריה ישראל - עברית - Ministry of Health

קימריה

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

אילאריס 150 מגמל ישראל - עברית - Ministry of Health

אילאריס 150 מגמל

novartis israel ltd - canakinumab - אבקה להכנת תמיסה לזריקה - canakinumab 150 mg / 1 ml - canakinumab - canakinumab - cryopyrin - associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight above 7.5 kg, including : - mucle - wells syndrome (mws), - neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), - severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.gouty arthritis:ilaris is indicated for the symptomatic treatment of adults patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

אילאריס 150 מגמל תמיסה להזרקה ישראל - עברית - Ministry of Health

אילאריס 150 מגמל תמיסה להזרקה

novartis israel ltd - canakinumab - תמיסה להזרקה - canakinumab 150 mg / 1 ml - canakinumab

יסקרטה ישראל - עברית - Ministry of Health

יסקרטה

gilead sciences israel ltd - axicabtagene ciloleucel - axicabtagene ciloleucel

טקארטוס ישראל - עברית - Ministry of Health

טקארטוס

gilead sciences israel ltd - anti-cd19 car t cells - anti-cd19 car t cells